Development of an Individualized Immune Prognostic Signature for Clear Cell Renal Cell Carcinoma through the Identification of Differential Immune Genes

Figure 5

Somatic mutations in the low- and high-risk groups and the potential for immunotherapy. Landscape of somatic mutations in the (a) low- and (b) high-risk groups of the top 20 genes. (c) Tumor mutation burden (TMB) and (d) microsatellite instability (MSI) in the low- and high-risk groups. (e) Predictable responder rate, (f) dysfunction score, (g) exclusion score, (h) myeloid-derived suppressor cells (MDSC), (i) tumor-associated fibroblasts (CAF), and (j) tumor-associated macrophages (TAM) M2 score of the low- and high-risk groups in the TCGA cohort. (k) Therapy response of sunitinib in the E-MTAB-3267 cohort and distribution of risk score with different response populations. (l) Risk score between patients with CR/PR and PD/SD; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)